SK92799A3 - Vitronectin receptor antagonists, process for their preparation, pharmaceutical composition them containing, their use and intermediates - Google Patents
Vitronectin receptor antagonists, process for their preparation, pharmaceutical composition them containing, their use and intermediates Download PDFInfo
- Publication number
- SK92799A3 SK92799A3 SK927-99A SK92799A SK92799A3 SK 92799 A3 SK92799 A3 SK 92799A3 SK 92799 A SK92799 A SK 92799A SK 92799 A3 SK92799 A3 SK 92799A3
- Authority
- SK
- Slovakia
- Prior art keywords
- mmol
- formula
- compound
- dibenzo
- vitronectin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3402697P | 1997-01-08 | 1997-01-08 | |
| PCT/US1998/000490 WO1998030542A1 (en) | 1997-01-08 | 1998-01-08 | Vitronectin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK92799A3 true SK92799A3 (en) | 1999-12-10 |
Family
ID=21873846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK927-99A SK92799A3 (en) | 1997-01-08 | 1998-01-08 | Vitronectin receptor antagonists, process for their preparation, pharmaceutical composition them containing, their use and intermediates |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6069158A (tr) |
| EP (1) | EP0977735B1 (tr) |
| JP (1) | JP2001508067A (tr) |
| KR (1) | KR20000069941A (tr) |
| CN (1) | CN1249745A (tr) |
| AP (1) | AP9901597A0 (tr) |
| AR (1) | AR010873A1 (tr) |
| AT (1) | ATE235467T1 (tr) |
| AU (1) | AU729641B2 (tr) |
| BG (1) | BG103548A (tr) |
| BR (1) | BR9806852A (tr) |
| CA (1) | CA2276738A1 (tr) |
| CO (1) | CO4920232A1 (tr) |
| DE (1) | DE69812602T2 (tr) |
| DZ (1) | DZ2395A1 (tr) |
| EA (1) | EA199900630A1 (tr) |
| ES (1) | ES2196534T3 (tr) |
| HU (1) | HUP0001945A3 (tr) |
| ID (1) | ID23168A (tr) |
| IL (1) | IL130760A0 (tr) |
| MA (1) | MA26462A1 (tr) |
| NO (1) | NO993350L (tr) |
| NZ (1) | NZ336560A (tr) |
| OA (1) | OA11076A (tr) |
| PE (1) | PE44799A1 (tr) |
| PL (1) | PL334499A1 (tr) |
| SK (1) | SK92799A3 (tr) |
| TR (1) | TR199901575T2 (tr) |
| WO (1) | WO1998030542A1 (tr) |
| ZA (1) | ZA9896B (tr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2304117A1 (en) * | 1997-09-04 | 1999-03-11 | Dirk A. Heerding | Integrin receptor antagonists |
| US6576643B2 (en) | 1997-09-19 | 2003-06-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DZ2609A1 (fr) * | 1997-09-19 | 2003-03-01 | Smithkline Beecham Corp | Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant. |
| US6420558B1 (en) | 1998-04-09 | 2002-07-16 | Meiji Seika Kaisha, Ltd. | Aminopiperidine derivates as integrin αvβ3 antagonists |
| JP4240424B2 (ja) * | 1998-10-23 | 2009-03-18 | エルジー ディスプレイ カンパニー リミテッド | エッチング剤及びこれを用いた電子機器用基板の製造方法 |
| US6339083B1 (en) | 1998-12-14 | 2002-01-15 | Bayer Aktiengesellschaft | Multiheterocyclic pharmAceuticals |
| EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | BENZAZEPINE DERIVATIVES FOR USE AS ANTAGONISTS OF THE INTEGRIN ALPHA-V RECEPTOR |
| DE19916837A1 (de) * | 1999-04-14 | 2000-10-19 | Merck Patent Gmbh | Dibenzoazulenderivate |
| US6750219B1 (en) | 1999-08-05 | 2004-06-15 | Meiji Seika Kaisha, Ltd. | Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity |
| DE19936780A1 (de) | 1999-08-09 | 2001-02-15 | Basf Ag | Neue Antagonisten von Integrinrezeptoren |
| FR2806082B1 (fr) * | 2000-03-07 | 2002-05-17 | Adir | Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU3943502A (en) | 2000-10-24 | 2002-05-27 | Merck & Co Inc | Dibenzoxazepine alpha v integrin receptor antagonist |
| RU2316337C2 (ru) | 2001-04-24 | 2008-02-10 | Мерк Патент Гмбх | КОМБИНИРОВАННАЯ ТЕРАПИЯ, ИСПОЛЬЗУЮЩАЯ АНТИАНГИОГЕННЫЕ СРЕДСТВА И TNF-α |
| WO2003059251A2 (en) | 2001-10-22 | 2003-07-24 | The Scripps Research Institute | Antibody targeting compounds |
| GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
| AU2012216372B2 (en) * | 2004-04-02 | 2015-01-22 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin |
| CA2562038C (en) * | 2004-04-02 | 2017-04-25 | The Regents Of The University Of California | Methods and compositions for treating and preventing disease associated with .alpha.v.beta.5 integrin |
| UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
| WO2006128689A2 (de) | 2005-05-31 | 2006-12-07 | Ralf Jochem | Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen |
| US20070122408A1 (en) * | 2005-10-20 | 2007-05-31 | The Scripps Research Institute | Fc Labeling for Immunostaining and Immunotargeting |
| EP2338518A1 (en) | 2006-01-18 | 2011-06-29 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
| BRPI0806596A2 (pt) | 2007-01-18 | 2013-07-23 | Merck Patent Ges Mit Berchraenkter Haftung | medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer |
| MX2010006972A (es) | 2007-12-21 | 2010-08-26 | Ligand Pharm Inc | Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos. |
| EP2395992A2 (en) | 2009-02-10 | 2011-12-21 | The Scripps Research Institute | Chemically programmed vaccination |
| MX2011012491A (es) | 2009-05-25 | 2011-12-14 | Merck Patent Gmbh | Administracion continua de cilengitida en tratamientos contra el cancer. |
| KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ａｖｂ５ 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
| BR112016027778A2 (pt) | 2014-05-30 | 2017-08-15 | Pfizer | Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica |
| WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794424A (fr) * | 1972-01-24 | 1973-07-23 | Science Union & Cie | Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament |
| US3906032A (en) * | 1972-11-10 | 1975-09-16 | Squibb & Sons Inc | Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof |
| IT1222986B (it) * | 1987-10-23 | 1990-09-12 | Texcontor Ets | Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo |
| US4994463A (en) * | 1987-12-14 | 1991-02-19 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic thromboxane A2 antagonists |
| DK0910563T3 (da) * | 1995-06-29 | 2003-09-01 | Smithkline Beecham Corp | Integrinreceptorantagonister |
| WO1997024124A1 (en) * | 1995-12-29 | 1997-07-10 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| CA2297910A1 (en) * | 1997-07-25 | 1999-02-04 | Smithkline Beecham Corporation | Vitronectin receptor antagonist |
| DZ2609A1 (fr) * | 1997-09-19 | 2003-03-01 | Smithkline Beecham Corp | Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant. |
-
1997
- 1997-12-30 CO CO97075531A patent/CO4920232A1/es unknown
-
1998
- 1998-01-02 MA MA24917A patent/MA26462A1/fr unknown
- 1998-01-05 AR ARP980100031A patent/AR010873A1/es not_active Application Discontinuation
- 1998-01-07 ZA ZA9896A patent/ZA9896B/xx unknown
- 1998-01-07 PE PE1998000013A patent/PE44799A1/es not_active Application Discontinuation
- 1998-01-08 BR BR9806852-0A patent/BR9806852A/pt not_active Application Discontinuation
- 1998-01-08 NZ NZ336560A patent/NZ336560A/xx unknown
- 1998-01-08 AP APAP/P/1999/001597A patent/AP9901597A0/en unknown
- 1998-01-08 TR TR1999/01575T patent/TR199901575T2/tr unknown
- 1998-01-08 CA CA002276738A patent/CA2276738A1/en not_active Abandoned
- 1998-01-08 EA EA199900630A patent/EA199900630A1/ru unknown
- 1998-01-08 HU HU0001945A patent/HUP0001945A3/hu unknown
- 1998-01-08 AT AT98902477T patent/ATE235467T1/de not_active IP Right Cessation
- 1998-01-08 KR KR1019997006154A patent/KR20000069941A/ko not_active Application Discontinuation
- 1998-01-08 IL IL13076098A patent/IL130760A0/xx unknown
- 1998-01-08 ID IDW990650D patent/ID23168A/id unknown
- 1998-01-08 WO PCT/US1998/000490 patent/WO1998030542A1/en not_active Application Discontinuation
- 1998-01-08 ES ES98902477T patent/ES2196534T3/es not_active Expired - Lifetime
- 1998-01-08 EP EP98902477A patent/EP0977735B1/en not_active Expired - Lifetime
- 1998-01-08 CN CN98802983A patent/CN1249745A/zh active Pending
- 1998-01-08 US US09/331,914 patent/US6069158A/en not_active Expired - Lifetime
- 1998-01-08 SK SK927-99A patent/SK92799A3/sk unknown
- 1998-01-08 AU AU59127/98A patent/AU729641B2/en not_active Ceased
- 1998-01-08 PL PL98334499A patent/PL334499A1/xx unknown
- 1998-01-08 JP JP53117598A patent/JP2001508067A/ja active Pending
- 1998-01-08 DE DE69812602T patent/DE69812602T2/de not_active Expired - Lifetime
- 1998-06-07 DZ DZ980005A patent/DZ2395A1/xx active
-
1999
- 1999-07-01 BG BG103548A patent/BG103548A/xx unknown
- 1999-07-07 NO NO993350A patent/NO993350L/no not_active Application Discontinuation
- 1999-07-08 OA OA9900155A patent/OA11076A/en unknown
-
2000
- 2000-04-18 US US09/551,743 patent/US6191304B1/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK92799A3 (en) | Vitronectin receptor antagonists, process for their preparation, pharmaceutical composition them containing, their use and intermediates | |
| AU738433B2 (en) | Vitronectin receptor antagonists | |
| AU9578798A (en) | Vitronectin receptor antagonist | |
| EP1146874B1 (en) | Vitronectin receptor antagonist | |
| US20020019387A1 (en) | Vitronectin receptor antagonist | |
| US6576643B2 (en) | Vitronectin receptor antagonists | |
| US20030216377A1 (en) | Vitronectin receptor antagonist | |
| CZ241599A3 (cs) | Antagonista vitronektinového receptorů | |
| CZ2000979A3 (cs) | Antagonista vitronektinového receptoru | |
| MXPA00002700A (en) | Vitronectin receptor antagonists | |
| MXPA01005547A (en) | Vitronectin receptor antagonist |